Literature DB >> 27345931

Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuations.

Neil B Hampson1, Karl D Kieburtz2, Peter A LeWitt3, Mika Leinonen4, Martin I Freed5.   

Abstract

BACKGROUND: Spirometry patterns suggesting restrictive and obstructive pulmonary dysfunction have been reported in Parkinson's disease (PD). However, the patterns' precise relation to PD pathophysiology remains unclear. Purpose/Aim. To assess ON- versus OFF-state pulmonary function, the quality of its spirometric evaluation, and the quality of longitudinal spirometric findings in a large sample of PD patients with motor fluctuations.
METHODS: During a placebo-controlled trial of an inhaled levodopa formulation, CVT-301, in PD patients with ≥2 h/d of OFF time, spirometry was performed by American Thoracic Society (ATS) guidelines at screening and throughout the 4-week treatment period.
RESULTS: Among 86 patients, mean motor impairment during an OFF state at screening was moderately severe. However, mean spirometry results at screening were within normal ranges, and in a mixed model for repeated measures (MMRM), the results at screening were not dependent on motor state (ON vs. OFF). In the placebo group (n = 43), 76% of ON-state and 81% of OFF-state examinations throughout the study met ATS quality metrics, and in an MMRM analysis, mean findings at these patients' arrivals for treatment-period visits showed no significant 4-week change. Across all 86 patients, flow-volume curves prior to any study-drug administration showed only a 3% incidence of "sawtooth" morphology.
CONCLUSIONS: In PD patients with motor fluctuations, longitudinal spirometry of acceptable quality was generally obtained. Although mean findings were normal, about a quarter of spirograms did not meet ATS quality criteria. Spirogram morphology may be less indicative of various forms of respiratory dysfunction than has previously been reported in PD.

Entities:  

Keywords:  CVT-301; Parkinson's disease; levodopa; pulmonary function; spirometry

Mesh:

Substances:

Year:  2016        PMID: 27345931     DOI: 10.1080/00207454.2016.1194274

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  4 in total

1.  Levodopa-responsive breathing discomfort in Parkinson's disease patients.

Authors:  Nicola Tambasco; Nicola Murgia; Pasquale Nigro; Federico Paolini Paoletti; Michele Romoli; Elona Brahimi; Marta Filidei; Simone Simoni; Giacomo Muzi; Paolo Calabresi
Journal:  J Neural Transm (Vienna)       Date:  2018-05-29       Impact factor: 3.575

Review 2.  Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Glenardi Glenardi; Tutwuri Handayani; Jimmy Barus; Ghea Mangkuliguna
Journal:  Neurol Clin Pract       Date:  2022-04

Review 3.  Profile of inhaled levodopa and its potential in the treatment of Parkinson's disease: evidence to date.

Authors:  Ami B Patel; Joohi Jimenez-Shahed
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-02       Impact factor: 2.570

4.  Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.

Authors:  Peter A LeWitt; Rajesh Pahwa; Alexander Sedkov; Ann Corbin; Richard Batycky; Harald Murck
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-11-21       Impact factor: 2.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.